Oculis logo.png
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
May 30, 2024 04:00 ET | Oculis Holding AG
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D....
Oculis Publishes Res
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
May 30, 2024 04:00 ET | Oculis Holding AG
ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) --Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS...
Oculis logo.png
Oculis updates share capital for its existing at-the-market offering program
May 17, 2024 16:30 ET | Oculis Holding AG
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the...
Oculis logo.png
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET | Oculis Holding AG
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
Oculis logo.png
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET | Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...
Oculis logo.png
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
May 08, 2024 16:05 ET | Oculis Holding AG
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON)Oculis also aims to complete an IND submission for...
Oculis logo.png
Oculis Publishes Invitation to the Annual General Meeting
May 07, 2024 16:05 ET | Oculis Holding AG
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on...
Oculis logo.png
Oculis to Present at Bank of America Global Healthcare Conference
May 06, 2024 06:30 ET | Oculis Holding AG
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to...
Oculis logo.png
Oculis Publishes Invitation to the Annual General Meeting
April 29, 2024 16:05 ET | Oculis Holding AG
ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held...
Oculis logo.png
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
April 22, 2024 09:27 ET | Oculis Holding AG
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ...